Related Experiment Videos
HIV risks, gender, and cocaine use among opiate users
1Institute of Behavioral Research, Texas Christian University, Fort Worth 76129.
Drug and Alcohol Dependence
|January 1, 1995
Summary
Cocaine use increases HIV risks for opiate-dependent individuals in methadone treatment. Cocaine use and gender interact, particularly for females engaging in high-risk sexual and injection behaviors.
Area of Science:
- Public Health
- Addiction Medicine
- Infectious Disease Epidemiology
Background:
- Opioid dependence is a significant public health issue.
- HIV remains a major concern among vulnerable populations, including injection drug users.
- Understanding co-occurring substance use and its impact on HIV risk behaviors is crucial for targeted interventions.
Purpose of the Study:
- To analyze HIV risks associated with injection and sex behaviors in relation to cocaine use and gender among opiate-dependent clients in methadone treatment.
- To identify specific risk factors and interactions between cocaine use and gender that influence HIV risk behaviors.
Main Methods:
- Cross-sectional analysis of 487 opiate-dependent clients undergoing methadone treatment.
- Assessment of HIV risky injection and sex behaviors.
- Evaluation of cocaine use patterns and gender differences.
Main Results:
- Cocaine users exhibited higher risks for HIV-related injection behaviors compared to non-cocaine users.
- Females demonstrated increased risk for HIV-related sex behaviors, including unprotected sex for drugs/money and sex with injection users.
- Interactions between cocaine use and gender were observed, with males showing a direct correlation between cocaine levels and HIV risk, while females exhibited high-risk behaviors at low-to-intermediate cocaine use levels.
Conclusions:
- Cocaine use significantly elevates HIV risks among opiate-dependent individuals in methadone treatment.
- Gender plays a critical role in modulating HIV risk behaviors, especially when combined with cocaine use.
- Findings underscore the need for tailored HIV risk reduction interventions within drug treatment programs, considering both substance use and gender-specific vulnerabilities.